No Data
CGN Technology: Report for the first quarter of 2025
CGN Technology: 2024 Annual Report
CGN Technology: 2024 Annual Report Summary
CGN Nuclear Technology Development (000881.SZ): Currently, the USA accounts for a very low market share of our company's overseas accelerator sales.
On April 16, Gelonghui reported that CGN Nuclear Technology Development (000881.SZ) stated on the investor interaction platform that 1. The company's proton therapy equipment manufacturing base has started production, with an initial supply capacity of about 4 proton therapy systems per year. In November 2024, the first piece of equipment from the company's proton therapy equipment manufacturing base will come off the production line, and this equipment is already ready for dispatch; the specific shipping time is still under negotiation with the customer. 2. In the first quarter, the company's New Materials business faced continued pressure on product prices in the market, covering multiple types of materials, with some products experiencing improved gross profit compared to the same period last year, while others still...
CGN Nuclear Technology Development (000881.SZ): The revenue from Overseas is relatively small.
On April 16, GELONGHUI reported that CGN Nuclear Technology Development (000881.SZ) stated on the interactive platform that the revenue from overseas is relatively small, and the current tariff issues have a minor impact on the company's income.
Retail Investors Are CGN Nuclear Technology Development Co., Ltd.'s (SZSE:000881) Biggest Owners and Were Hit After Market Cap Dropped CN¥548m
CGN Nuclear Technology Development Co., Ltd. (SZSE:000881) Surges 25% Yet Its Low P/S Is No Reason For Excitement
